Investigational drug · Phase 2
BRM421
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Dry Eye Disease (DED), Keratoconjunctivitis Sicca.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 20, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
5
Any phase or sponsor naming "BRM421"
First trial start
2025
Dec 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BRM421", any sponsor or status.
Conditions studied
As listed on its trial records.
- Dry Eye Disease (DED)
- Keratoconjunctivitis Sicca
Approved drugs for the same conditions: Dry eye disease · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "BRM421" as an intervention, largest first.
- Assessment of the Safety and Efficacy of BRM421 Ophthalmic Solutions in Dry Eye Subjects.Pivotal-lookingCompleted
BRIM Biotechnology Inc.Industry
NCT05695781 · 740 participants · Start Feb 27, 2023 · Primary completion Dec 30, 2023
Drug: BRM421 Ophthalmic Solution; Vehicle · For: Dry Eye Disease
Sites: Warwick, Rhode Island
- Safety and Efficacy of BRM421 for Dry Eye Syndrome TreatmentPivotal-lookingCompleted
BRIM Biotechnology Inc.Industry
NCT04343287 · 220 participants · Start Jan 15, 2020 · Primary completion Jun 23, 2020
Drug: BRM421; Placebo · For: Dry Eye Syndrome
Sites: Newport Beach, California; Indianapolis, Indiana; Andover, Massachusetts · 4 sites in all
- Safety and Efficacy of BRM421 for Dry Eye SyndromePivotal-lookingCompleted
BRIM Biotechnology Inc.Industry
NCT03066219 · 157 participants · Start Feb 7, 2017 · Primary completion May 20, 2017
Drug: BRM421; Placebo · For: Dry Eye Syndrome
Sites: Lewiston, Maine; Andover, Massachusetts
- A Dose Regimen Study of BRM421 Ophthalmic Solution in Patients With Dry Eye DiseaseNot yet recruiting
BRIM Biotechnology Inc.Industry
NCT07078955 · 99 participants (planned) · Start Dec 2025 · Primary completion Nov 2026
Drug: BRM421 Ophthalmic Solution, 0.03%; Artificial Tear and 1 more · For: Dry Eye Disease (DED); Keratoconjunctivitis Sicca
Sites: New Taipei City, Taiwan
BRIM Biotechnology Inc.Industry
NCT07422389
Drug: BRM421 Ophthalmic Solution, 0.06% · For: Limbal Stem Cell Deficiency (LSCD)
Sites: Philadelphia, Pennsylvania
Newest research
PubMed records naming it or its code names, newest first.
- Quintessence of currently approved and upcoming treatments for dry eye disease.
Patil S, Sawale G, Ghuge S, et al. · Graefes Arch Clin Exp Ophthalmol 2025
Also in development for Dry Eye Disease (DED)
- DFL24498Phase 32 trials
Dompé Farmaceutici S.p.A · Dry Eye Disease (DED), Atopic Keratoconjunctivitis
- licaminlimabPhase 31 trial
Oculis · Dry Eye Disease (DED)
- 0.25% RCI001RCI001Phase 22 trials
ORA, Inc. · Dry Eye Disease (DED), Dry Eye
- TTAX03Phase 22 trials
BioTissue Holdings, Inc · Knee Osteoarthritis, Knee Pain Chronic, Knee Arthritis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.